Navigation Links
WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
Date:7/10/2012

FREMONT, Calif., July 10, 2012 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today the commercial launch of MyDesign – an open format product offering for its SmartChip System.  The key feature of MyDesign is that it allows customers to dispense their own assays in a variety of configurations, thus enabling an easy and rapid design of new experiments.  After loading their custom content on MyDesign SmartChips, customers will be able to perform accurate high-throughput qPCR gene expression and single nucleotide polymorphism (SNP) genotyping projects in a simpler and more cost-effective way.  Relative to competitive offerings, it is believed that the new SmartChip System has best-in-class flexibility, high levels of sensitivity and dynamic range without the need for preamplification, and a very low cost per reaction.  Management believes that these features will position the Company to become a leading provider of high-throughput qPCR solutions. 

"The MyDesign concept has greatly expanded our ability to utilize the SmartChip System in our laboratory.  We were able to successfully conduct diverse experiments such as long non-coding RNA (lncRNA) expression analysis, as well as perform genotyping and target enrichment for next-generation sequencing. The ability to dispense assays on the spot and to test different configurations has significantly increased the speed of content selection and validation. We are looking forward to deploying the platform in a number of future studies requiring high-throughput qPCR solutions," stated Dr. Jo Vandesompele, Professor of Functional Genomics and Applied Bioinformatics at Ghent University.   

In conjunction with the MyDesign launch, WaferGen established a relationship with Integrated DNA Technologies (IDT) to provide PrimeTime qPCR Primers for SYBR-based gene expression assays. Over 800,000 such assays were developed by IDT using a sophisticated design engine that eliminates cross reactivity and includes up-to-date SNP and intron/exon junction information. The two companies will also collaboratively provide custom assay design services for FFPE-derived samples to WaferGen customers.

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers the SmartChip Real-Time PCR System—a next-generation genetic analysis platform for profiling and validating molecular biomarkers. It provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling as well as single nucleotide polymorphism (SNP) genotyping.   

For additional information, please see: http://www.wafergen.com

Forward Looking Statements

This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits to the Company of its new open format qPCR platform and strategic realignment, the expected competitive advantages of the new SmartChip System and expected benefits to the Company of these competitive advantages, the expected benefits to customers of the new SmartChip System, the expected amount of reduction in monthly expenses to be achieved as a result of organizational changes and other statements relating to future events are not historical facts, including statements which may be preceded by the words "will," "believes" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2011. Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

WaferGen Contact:

John Harland
john.harland@wafergen.com
510-780-2395



'/>"/>
SOURCE WaferGen Bio-systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nouveau Life Pharmaceuticals (NOUV) Launches Affiliate Sales Program
2. Marken Launches New Global Regulatory Consultation Services
3. Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
4. Bulgaria Launches Development of National Hepatitis Plan
5. Fidelitas Launches Unique Methadone Documentation and Dispensing System in Canada
6. Mylan Launches Thiamine Hydrochloride Injection
7. PeriGen, Inc. Launches Consumer Safety Campaign to Raise Awareness of Dangerous Birth Complication
8. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
9. Konica Minolta Sensing America Launches Spanish Website in Support of Growing Demand In Latin American Countries
10. The Michael J. Fox Foundation Launches The $14 Million-Edmond J. Safra Core Programs for PD Research
11. Lifescript Launches New Online Asthma Health Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 ReNeuron reported in December 2016 ... chronic stroke patients, despite not meeting the three-month time frame ... Action Research Arm Test (ARAT). As a result, the company ... clinical study in 2017. Beyond CTX, we expect safety and ... and Phase I data from its critical limb ischaemia (CLI) ...
(Date:3/22/2017)... -- ReportsnReports.com adds Global Vagus Nerve Stimulation ... global vagus nerve stimulation market analyst says one trend ... invasive VNS procedures. Few years ago, VNS procedures were ... high standards of healthcare infrastructure. ... Browse 30 Exhibits, ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, ... ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR language ...
(Date:3/23/2017)... ... ... and Back”: a true-life testimony of tragedy and the miraculous power of God to ... mother and grandmother committed to sharing her many spiritual adventures which affirm God’s grace ... actual events in the life of her family, which validate her deep faith in ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
Breaking Medicine News(10 mins):